Inside The COVID-19 Pipeline
An Interactive View Of Vaccines & Treatments In Development
Updated daily as additional research gets underway, this pipeline tracker follows the global effort to find drugs that could help treat COVID-19 and the symptoms it causes, and accelerate a vaccine that could help limit the spread of the pandemic.

More from COVID-19
- • By
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
- • By
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
- • By
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
- • By
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.






